Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD19 CAR-T cells with immunosuppressive receptor knockdown
- Development stage
- Unknown
- Lead developer
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Anti-CD19 CAR-T cells with immunosuppressive receptor knockdown is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by The Sixth Affiliated Hospital of Sun Yat-sen University. The therapy consists of T cells engineered to express a CAR targeting the CD19 antigen, which is prevalent on B-cell malignancies. Additionally, these cells are modified using genetic knockdown techniques to reduce the expression of immunosuppressive receptors, aiming to enhance the persistence and anti-tumor efficacy of the CAR-T cells within the inhibitory tumor microenvironment. It is primarily being investigated in Phase 0/1 clinical trials for the treatment of relapsed or refractory B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.
- Other names
- anti-CD19 CAR-T cells with immunosuppressive receptor knockdownanti-CD-19 CAR-T cells with immunosuppressive receptor knockdownanti-CD 19 CAR-T cells with immunosuppressive receptor knockdown
02
Targets
Beyond the preview
Go deeper on anti-CD19 CAR-T cells with immunosuppressive receptor knockdown.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD19 CAR-T cells with immunosuppressive receptor knockdown.